---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-23-002648"
form_type: "8-K"
ticker: null
cik: "0000910267"
company_name: "TITAN PHARMACEUTICALS INC"
filed_at: "2023-04-11T23:59:59+00:00"
generated_at: "2026-06-17T03:58:01.594212+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Titan Pharma receives Nasdaq deficiency notice for stockholders' equity below $2.5M

## Summary
- Stockholders' equity of $1.363M as of Dec 31, 2022, below Nasdaq's $2.5M minimum.
- Company has 45 days to submit a compliance plan; may get up to 180 days to cure.
- 2022 annual meeting set for June 19, 2023; record date May 1, 2023.
- Shareholder proposals due by April 24, 2023 for inclusion in proxy materials.
- Listing on Nasdaq Capital Market unaffected for now while company evaluates options.

## SEC filing metadata
- accession: 0001829126-23-002648
- form_type: 8-K
- cik: 0000910267
- company_name: TITAN PHARMACEUTICALS INC
- filed_at: 2023-04-11T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 5.08, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/910267/000182912623002648/0001829126-23-002648-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/910267/000182912623002648/titanpharma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-23-002648
- JSON: https://secwatch.observer/filing/0001829126-23-002648.json
- Plain text: https://secwatch.observer/filing/0001829126-23-002648.txt

## Key facts
- Listing & Compliance Notices
  TITAN PHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2,500,000. In its 2022 10-K, the Company reported stockholders’ equity of $1,363,000, and, as a result, does not currently satisfy Nasdaq Marketplace Rule 5550(b)(1). The Notice has no immediate effect on the Company’s listing on the Nasdaq Capital Market. In
  evidence_url: https://www.sec.gov/Archives/edgar/data/910267/000182912623002648/0001829126-23-002648-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.